DBV Technologies reports Q1 net loss $27.3M; cash runway only through Dec 2024, substantial doubt

DBV Technologies S.A.

2024-Q1 EPS reported -$0.28 revenue$1,407,000

Cash & equivalents $101.5M as of March 31, down from $141.4M at Dec 31, 2023.
Net loss of $27.3M ($0.28 per share) vs $20.6M loss in Q1 2023, driven by R&D spending on VITESSE.
Operating cash burn $34.7M in Q1 2024; company warns cash insufficient for 12 months, requires additional capital.
VITESSE Phase 3 enrollment on track to screen last patient by Q3 2024; 86 sites in US, Canada, Europe, UK, Australia.
Appointed Robert Pietrusko as Chief Regulatory Officer; he led over 35 BLA/NDA/MAA approvals globally.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

DBV Technologies S.A. reported the first quarter ended March 31, 2024 results: net income (27,3), EPS (0,28).

Period: the first quarter ended March 31, 2024
Net income: (27,3)
EPS: (0,28)
Result: reported results

Exact text from the filing

DBV Technologies Reports First Quarter 2024 Financial Results and Business Update

View on SEC.gov

1435 earnings releases filed in the last 30 days. Browse all earnings releases →

DBV Technologies S.A. filing history →

Source: SEC EDGAR

accession 0001193125-24-133209

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.